Surveillance Strategies Following Curative Therapy for Localized Renal Cell Carcinoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2008

AUTHORS

Vitaly Margulis , Surena F. Matin , Christopher G. Wood

ABSTRACT

Advances in the diagnosis, staging, and treatment of patients with renal cell carcinoma (RCC) have resulted in improved survival pf patients with locally recurrent and metastatic disease. Assuming that success of clinical intervention at the time of relapse is inversely proportional to the disease burden at the time of salvage treatment, ideal surveillance protocol should allow the earliest identification of potentially treatable recurrences while minimizing unnecessary examinations and patients anxiety. In addition, optimal surveillance regimen would take into account primary tumor characteristics; initial treatment modality; incidence, timing, and pattern of recurrence; and effectiveness of available salvage treatments. Anatomic tumor stage remains the most important prognosticator of outcome in RCC and a cornerstone of several currently. proposed surveillance strategies. Nonetheless, recent identification of novel clinical and pathologic prognostic factors in RCC have resulted in gradual transition from the use of solitary clinical factors, such as tumor, node, metastasis staging system, to the introduction of systems that integrate multiple validated prognostic factors. Finally, development of new and meaningful biomarkers and their incorporation into integrated staging algorithms will likely revolutionize the staging and surveillance of RCC patients. More... »

PAGES

265-273

Book

TITLE

Clinical Management of Renal Tumors

ISBN

978-1-58829-251-3
978-1-60327-149-3

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-60327-149-3_16

DOI

http://dx.doi.org/10.1007/978-1-60327-149-3_16

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1002795946


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, MD Anderson Cancer Center, Houston, TX", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, MD Anderson Cancer Center, Houston, TX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Margulis", 
        "givenName": "Vitaly", 
        "id": "sg:person.0700013535.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700013535.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, MD Anderson Cancer Center, Houston, TX", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, MD Anderson Cancer Center, Houston, TX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matin", 
        "givenName": "Surena F.", 
        "id": "sg:person.0675713004.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675713004.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, MD Anderson Cancer Center, Houston, TX", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, MD Anderson Cancer Center, Houston, TX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008", 
    "datePublishedReg": "2008-01-01", 
    "description": "Advances in the diagnosis, staging, and treatment of patients with renal cell carcinoma (RCC) have resulted in improved survival pf patients with locally recurrent and metastatic disease. Assuming that success of clinical intervention at the time of relapse is inversely proportional to the disease burden at the time of salvage treatment, ideal surveillance protocol should allow the earliest identification of potentially treatable recurrences while minimizing unnecessary examinations and patients anxiety. In addition, optimal surveillance regimen would take into account primary tumor characteristics; initial treatment modality; incidence, timing, and pattern of recurrence; and effectiveness of available salvage treatments. Anatomic tumor stage remains the most important prognosticator of outcome in RCC and a cornerstone of several currently. proposed surveillance strategies. Nonetheless, recent identification of novel clinical and pathologic prognostic factors in RCC have resulted in gradual transition from the use of solitary clinical factors, such as tumor, node, metastasis staging system, to the introduction of systems that integrate multiple validated prognostic factors. Finally, development of new and meaningful biomarkers and their incorporation into integrated staging algorithms will likely revolutionize the staging and surveillance of RCC patients.", 
    "editor": [
      {
        "familyName": "Bukowski", 
        "givenName": "Ronald M.", 
        "type": "Person"
      }, 
      {
        "familyName": "Novick", 
        "givenName": "Andrew C.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-60327-149-3_16", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-58829-251-3", 
        "978-1-60327-149-3"
      ], 
      "name": "Clinical Management of Renal Tumors", 
      "type": "Book"
    }, 
    "keywords": [
      "renal cell carcinoma", 
      "salvage treatment", 
      "prognostic factors", 
      "cell carcinoma", 
      "surveillance strategies", 
      "Localized Renal Cell Carcinoma", 
      "optimal surveillance regimen", 
      "initial treatment modality", 
      "primary tumor characteristics", 
      "time of relapse", 
      "patterns of recurrence", 
      "pathologic prognostic factors", 
      "treatment of patients", 
      "metastasis (TNM) staging system", 
      "treatable recurrences", 
      "metastatic disease", 
      "improved survival", 
      "surveillance regimen", 
      "important prognosticator", 
      "clinical factors", 
      "curative therapy", 
      "tumor characteristics", 
      "RCC patients", 
      "tumor stage", 
      "staging system", 
      "surveillance protocol", 
      "treatment modalities", 
      "disease burden", 
      "patient anxiety", 
      "unnecessary examinations", 
      "early identification", 
      "clinical interventions", 
      "patients", 
      "staging algorithm", 
      "meaningful biomarkers", 
      "carcinoma", 
      "recurrence", 
      "staging", 
      "treatment", 
      "recent identification", 
      "regimen", 
      "relapse", 
      "prognosticator", 
      "therapy", 
      "tumors", 
      "factors", 
      "incidence", 
      "recurrent", 
      "disease", 
      "diagnosis", 
      "biomarkers", 
      "survival", 
      "intervention", 
      "outcomes", 
      "modalities", 
      "burden", 
      "surveillance", 
      "examination", 
      "anxiety", 
      "cornerstone", 
      "identification", 
      "strategies", 
      "protocol", 
      "time", 
      "timing", 
      "use", 
      "advances", 
      "stage", 
      "patterns", 
      "addition", 
      "development", 
      "effectiveness", 
      "success", 
      "nodes", 
      "characteristics", 
      "incorporation", 
      "introduction", 
      "system", 
      "gradual transition", 
      "introduction of systems", 
      "transition", 
      "algorithm"
    ], 
    "name": "Surveillance Strategies Following Curative Therapy for Localized Renal Cell Carcinoma", 
    "pagination": "265-273", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1002795946"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-60327-149-3_16"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-60327-149-3_16", 
      "https://app.dimensions.ai/details/publication/pub.1002795946"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_386.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-60327-149-3_16"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-60327-149-3_16'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-60327-149-3_16'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-60327-149-3_16'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-60327-149-3_16'


 

This table displays all metadata directly associated to this object as RDF triples.

160 TRIPLES      22 PREDICATES      107 URIs      100 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-60327-149-3_16 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N5b0e464a1d64443fb28192537d511b6a
4 schema:datePublished 2008
5 schema:datePublishedReg 2008-01-01
6 schema:description Advances in the diagnosis, staging, and treatment of patients with renal cell carcinoma (RCC) have resulted in improved survival pf patients with locally recurrent and metastatic disease. Assuming that success of clinical intervention at the time of relapse is inversely proportional to the disease burden at the time of salvage treatment, ideal surveillance protocol should allow the earliest identification of potentially treatable recurrences while minimizing unnecessary examinations and patients anxiety. In addition, optimal surveillance regimen would take into account primary tumor characteristics; initial treatment modality; incidence, timing, and pattern of recurrence; and effectiveness of available salvage treatments. Anatomic tumor stage remains the most important prognosticator of outcome in RCC and a cornerstone of several currently. proposed surveillance strategies. Nonetheless, recent identification of novel clinical and pathologic prognostic factors in RCC have resulted in gradual transition from the use of solitary clinical factors, such as tumor, node, metastasis staging system, to the introduction of systems that integrate multiple validated prognostic factors. Finally, development of new and meaningful biomarkers and their incorporation into integrated staging algorithms will likely revolutionize the staging and surveillance of RCC patients.
7 schema:editor N5e0aff1ce9154da0a184c9cd49eef141
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nf1f9988b14ce4e5abf47930e2a5cf115
11 schema:keywords Localized Renal Cell Carcinoma
12 RCC patients
13 addition
14 advances
15 algorithm
16 anxiety
17 biomarkers
18 burden
19 carcinoma
20 cell carcinoma
21 characteristics
22 clinical factors
23 clinical interventions
24 cornerstone
25 curative therapy
26 development
27 diagnosis
28 disease
29 disease burden
30 early identification
31 effectiveness
32 examination
33 factors
34 gradual transition
35 identification
36 important prognosticator
37 improved survival
38 incidence
39 incorporation
40 initial treatment modality
41 intervention
42 introduction
43 introduction of systems
44 meaningful biomarkers
45 metastasis (TNM) staging system
46 metastatic disease
47 modalities
48 nodes
49 optimal surveillance regimen
50 outcomes
51 pathologic prognostic factors
52 patient anxiety
53 patients
54 patterns
55 patterns of recurrence
56 primary tumor characteristics
57 prognostic factors
58 prognosticator
59 protocol
60 recent identification
61 recurrence
62 recurrent
63 regimen
64 relapse
65 renal cell carcinoma
66 salvage treatment
67 stage
68 staging
69 staging algorithm
70 staging system
71 strategies
72 success
73 surveillance
74 surveillance protocol
75 surveillance regimen
76 surveillance strategies
77 survival
78 system
79 therapy
80 time
81 time of relapse
82 timing
83 transition
84 treatable recurrences
85 treatment
86 treatment modalities
87 treatment of patients
88 tumor characteristics
89 tumor stage
90 tumors
91 unnecessary examinations
92 use
93 schema:name Surveillance Strategies Following Curative Therapy for Localized Renal Cell Carcinoma
94 schema:pagination 265-273
95 schema:productId N5f758f13168643fca56aa924f8802aee
96 Ne0a37c14274449219b6bdff5c46e8e5d
97 schema:publisher N128d6009257c46efa6e5ef0ad42ccf22
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002795946
99 https://doi.org/10.1007/978-1-60327-149-3_16
100 schema:sdDatePublished 2022-09-02T16:15
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher Nfdd784d5a7d84e898a7c18ba0d688f30
103 schema:url https://doi.org/10.1007/978-1-60327-149-3_16
104 sgo:license sg:explorer/license/
105 sgo:sdDataset chapters
106 rdf:type schema:Chapter
107 N0e8b931224a6494aa364ebb4890bf6f0 rdf:first sg:person.0675713004.57
108 rdf:rest Ncedf07560aa44897aa3092fb08ea85b8
109 N128d6009257c46efa6e5ef0ad42ccf22 schema:name Springer Nature
110 rdf:type schema:Organisation
111 N5b0e464a1d64443fb28192537d511b6a rdf:first sg:person.0700013535.70
112 rdf:rest N0e8b931224a6494aa364ebb4890bf6f0
113 N5ddc8df7c66241968970e2dcd03fd20b schema:familyName Novick
114 schema:givenName Andrew C.
115 rdf:type schema:Person
116 N5e0aff1ce9154da0a184c9cd49eef141 rdf:first N768aa1344a6c496ca1cffdd6e861f3c3
117 rdf:rest Nc29f79b9011a4913944bd9df6c8f6511
118 N5f758f13168643fca56aa924f8802aee schema:name dimensions_id
119 schema:value pub.1002795946
120 rdf:type schema:PropertyValue
121 N768aa1344a6c496ca1cffdd6e861f3c3 schema:familyName Bukowski
122 schema:givenName Ronald M.
123 rdf:type schema:Person
124 Nc29f79b9011a4913944bd9df6c8f6511 rdf:first N5ddc8df7c66241968970e2dcd03fd20b
125 rdf:rest rdf:nil
126 Ncedf07560aa44897aa3092fb08ea85b8 rdf:first sg:person.01040121722.56
127 rdf:rest rdf:nil
128 Ne0a37c14274449219b6bdff5c46e8e5d schema:name doi
129 schema:value 10.1007/978-1-60327-149-3_16
130 rdf:type schema:PropertyValue
131 Nf1f9988b14ce4e5abf47930e2a5cf115 schema:isbn 978-1-58829-251-3
132 978-1-60327-149-3
133 schema:name Clinical Management of Renal Tumors
134 rdf:type schema:Book
135 Nfdd784d5a7d84e898a7c18ba0d688f30 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
138 schema:name Medical and Health Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
141 schema:name Oncology and Carcinogenesis
142 rdf:type schema:DefinedTerm
143 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
144 schema:familyName Wood
145 schema:givenName Christopher G.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
147 rdf:type schema:Person
148 sg:person.0675713004.57 schema:affiliation grid-institutes:grid.240145.6
149 schema:familyName Matin
150 schema:givenName Surena F.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675713004.57
152 rdf:type schema:Person
153 sg:person.0700013535.70 schema:affiliation grid-institutes:grid.240145.6
154 schema:familyName Margulis
155 schema:givenName Vitaly
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700013535.70
157 rdf:type schema:Person
158 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, MD Anderson Cancer Center, Houston, TX
159 schema:name Department of Urology, MD Anderson Cancer Center, Houston, TX
160 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...